Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?

Stroke

Volumn 36, Issue 2, 2005, Pages 360-366

  Miller, Paul S J ^a   Andersson, Fredrik L ^b   Kalra, Lalit ^c  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anticoagulants; Arrhythmia; Cost benefit analysis; Primary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; WARFARIN;

ADULT; AGED; ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; ISCHEMIA; MEDLINE; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 12844285578     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000153002.56324.8c     Document Type: Review

References (56)

1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health. 2001;4:225-250.
2. Sullivan SD, Lyles A, Luce B, Grigar J. AMCP Guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organisations. J Manag Care Pharm. 2001;7:272-282.
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
4. Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet. 1997;350:943-950.
5. Ryder KM and Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1999;84:131R-138R.
6. Morgan S, and Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract. 2002;52:373-380.
7. Stewart S, Murphy N, Walker A, McGuire A, McMurray J. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90:286-292.
8. Steinberg J. Atrial fibrillation: an emerging epidemic? Heart. 2004;90:239-240.
9. Go AS, Hylek EM, Phillips KA, Chang Y, Renault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
10. Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392-398.
11. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke. 1983;14:664-667.
12. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke. 1985;16:182-188.
13. Candelise L, Pinardi G, Morabito A. Mortality in acute stroke with atrial fibrillation. The Italian acute stroke study group. Stroke. 1991;22:169-174.
14. Gustafsson C, Britton M. Pathogenetic mechanism of stroke in non-valvular atrial fibrillation: follow-up of stroke patients with and without atrial fibrillation. J Intern Med. 1991;230:11-16.
15. Broderick JP, Phillips SJ, Ofallen WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke. 1992;23:1250-1256.
16. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, Booyakarnkul S, Warlow C. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ. 1992;305:1460-1465.
17. Censori B, Camerlingo M, Casto L, Ferraro B, Gazzaniga GC, Cesana B, Mamoli A. Prognostic factors in first-ever stroke in the carotid artery territory seen within 6 hours after onset. Stroke. 1993;24:532-535.
18. Anderson CS, Jamrozik KD, Broadhurst RJ, Stewart-Wynne EG. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth community Stroke Study. Stroke. 1994;25:1935-1944.
19. Lin HJ, Wolf PA, Keiiy-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760-1764.
20. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765-1769.
21. Appelros P, Nydevik I, Seiger A, Terent A. Predictors of severe stroke. Influence of pre-existing dementia and cardiac disorders. Stroke. 2002;33:2357-2362.
22. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke. Predictors for death, dependency, and recurrent stroke within the first year. Stroke. 2003;34:122-126.
23. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22:118-123.
24. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
25. Pagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883-890.
26. Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ, Donnan GA. Lifetime cost of stroke subtypes in Australia: findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2003;34:2502-2507.
27. Bergman L, van der Meulen JH, Limburg M, Habbema JD. Costs of medical care after first-ever stroke in The Netherlands. Stroke. 1995;26:1830-1836.
28. Persson U, Silverberg R, Lindgren B, Norrving B, Jadback G, Johansson B, Puranen BI. Direct costs of stroke for a Swedish population. Int J Technol Assess Health Care. 1990;6:125-137.
29. Terént A, Marké LA, Asplund K, Norrving B, Jonsson E, Wester PO. Costs of stroke in Sweden: a national perspective. Stroke. 1994;25:2363-2369.
30. Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med. 1999;246:151-159.
31. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics. 2003;21:651-659.
32. Ghatnekar O, Persson U, Glader EL, Terént A. The cost of stroke in Sweden-an incidence estimate. Int J Technol Assessment Health Care. 2004;20:375-380.
33. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke. 1998;29:1827-1832.
34. Caro JJ, Huybrechts KF for the Stroke Economic Analysis Group. Stroke treatment economic model (STEM): predicting long-term costs from functional status. Stroke. 1999;30:2574-2579.
35. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003;21:43-50.
36. Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW, Diener HC. German Stroke Data Bank Collaborators. Management patterns and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis. 2003;15:29-36.
37. Spieler JF, De Pouvourville G, Amarenco P. Cost of a recurrent vs cost of first-ever stroke over an 18-month period. Eur J Neurol. 2003;10:621-624.
38. Carod-Artal FJ, Egido-Navarro JA, Gonzalez-Gutierrez JL, Varela de Seijas E. Direct cost of cerebrovascular disease during the first year of follow-up. Rev Neurol. 1999;29:1353-1355.
39. US Department of Labor, Bureau of Labor Statistics, Consumer Price Indexes. Inflation calculator. http://www.bls.gov/cpi/home.htm. Accessed April 2004.
40. Organisation for Economic Co-operation and Development. Purchasing Power Parities (PPP), statistics, data and indicators: PPPs and derived indices for all OECD countries, April 2004. Available at http:// www.oecd.org/ statisticsdata/0,2643,en_2649_34357_1_119656_1_ 1_1,00.html. Accessed April 2004.
41. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229-234.
42. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke I. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-1460.
43. Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest. 1992;102:538s-549s.
44. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
45. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998;29:1083-1091.
46. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956-962.
47. Desbiens N. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. J Am Geriatr Soc. 2002;50:863-869.
48. Samsa GP, Matchar DB, Phillips DL, McGrann J. Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making. J Thromb Thrombolys. 2002;14:103-111.
49. Grieve R, Hutton J, Bhalla A, Rastenyte D, Ryglewicz D, Sarti C, Lamassa M, Giroud M, Dundas R, Wolfe CD. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke. 2001;32:1684-1691.
50. Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
51. Chang KC, Su IJ, Tsai ST, Shieh DB, Jin YT. Prediction of length of stay of first-ever ischemic stroke. Stroke. 2002;33:2670-2674.
52. Porsdal V, and Boysen G. Direct costs during the first year after intracerebral haemorrhage. Eur J Neurol. 1999;6:449-454.
53. Claesson L, Gosman-Hedstrom G, Johanesson M, Fagerberg B, Blomstrand C. Resource utilization and costs of stroke unit care integrated in a care continuum: a 1-year controlled, prospective, randomized study in elderly patients. The Goteborg 70+ Stroke Study. Stroke. 2000;31:2569-2577.
54. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
55. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
56. Pengo V, Legnani C, Noventa F, Palareti G. ISCOAT Study Group. (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001;85:418-422.